Increase in myofibrillar Ca2+ sensitivity induced by UD-CG 212 Cl, an active metabolite of pimobendan, in canine ventricular myocardium
- PMID: 11210003
- DOI: 10.1097/00005344-200102000-00008
Increase in myofibrillar Ca2+ sensitivity induced by UD-CG 212 Cl, an active metabolite of pimobendan, in canine ventricular myocardium
Abstract
We performed experiments in canine ventricular trabeculae loaded with aequorin to elucidate the mechanism of positive inotropic effect of UD-CG 212 Cl (4,5-dihydro-6-[2-(4-hydroxyphenyl)-1H-benzimidazole-5-yl]-5-methyl-3(2H)-pyridazinone), an active metabolite of pimobendan. The maximum response to UD-CG 212 Cl achieved at 10(-5) M was 18% of ISOmax and it was associated with an increase in Ca2+ transients of 7% of ISOmax. For a given increase in force, the increase in Ca2+ transients induced by UD-CG 212 Cl was less than that induced by elevation of [Ca2+]o. The positive inotropic effect of UD-CG 212 Cl was not associated with an impairment of relaxation and it was abolished by carbachol. In conclusion, UD-CG 212 Cl has a positive inotropic effect partly due to an increase in myofibrillar Ca2+ sensitivity that is exerted via cross talk with a signal transduction pathway that involves cAMP.
Similar articles
-
Decrease in Ca(2+)-sensitizing effect of UD-CG 212 Cl, a metabolite of pimobendan, under acidotic condition in canine ventricular myocardium.J Pharmacol Exp Ther. 2001 Sep;298(3):1060-6. J Pharmacol Exp Ther. 2001. PMID: 11504803
-
Different mechanisms involved in the positive inotropic effects of benzimidazole derivative UD-CG 115 BS (pimobendan) and its demethylated metabolite UD-CG 212 Cl in canine ventricular myocardium.J Cardiovasc Pharmacol. 1991 Mar;17(3):365-75. doi: 10.1097/00005344-199103000-00003. J Cardiovasc Pharmacol. 1991. PMID: 1711596
-
Reversal of phosphate induced decreases in force by the benzimidazole pyridazinone, UD-CG 212 CL, in myofilaments from human ventricle.Mol Cell Biochem. 1997 Nov;176(1-2):83-8. Mol Cell Biochem. 1997. PMID: 9406148
-
Mechanisms of action of novel cardiotonic agents.J Cardiovasc Pharmacol. 2002 Sep;40(3):323-38. doi: 10.1097/00005344-200209000-00001. J Cardiovasc Pharmacol. 2002. PMID: 12198318 Review.
-
Mechanism of action of Ca2+ sensitizers--update 2001.Cardiovasc Drugs Ther. 2001 Sep;15(5):397-403. doi: 10.1023/a:1013385305567. Cardiovasc Drugs Ther. 2001. PMID: 11855658 Review.
Cited by
-
Small Molecules acting on Myofilaments as Treatments for Heart and Skeletal Muscle Diseases.Int J Mol Sci. 2020 Dec 16;21(24):9599. doi: 10.3390/ijms21249599. Int J Mol Sci. 2020. PMID: 33339418 Free PMC article. Review.
-
Effect of pimobendan in patients with chronic heart failure.Exp Clin Cardiol. 2001 Winter;6(4):195-9. Exp Clin Cardiol. 2001. PMID: 20428258 Free PMC article.
-
Increased myofilament Ca2+-sensitivity and arrhythmia susceptibility.J Mol Cell Cardiol. 2010 May;48(5):824-33. doi: 10.1016/j.yjmcc.2010.01.011. Epub 2010 Jan 22. J Mol Cell Cardiol. 2010. PMID: 20097204 Free PMC article. Review.
-
Inotropic effects of a single intravenous recommended dose of pimobendan in healthy dogs.J Vet Med Sci. 2019 Jan 8;81(1):22-25. doi: 10.1292/jvms.18-0185. Epub 2018 Nov 8. J Vet Med Sci. 2019. PMID: 30404952 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous